# Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

> **NCT00368797** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 125 (actual)

## Conditions studied

- Peripheral Arterial Disease

## Interventions

- **DRUG:** XRP0038 (NV1FGF)

## Key facts

- **NCT ID:** NCT00368797
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2008-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368797, "Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00368797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*